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Marine fungi as a good source for new natural products   
Though marine fungi are a potent group of secondary metabolite 
producers, they are not well characterised and underutilised in 
terms of biotechnological application. Here, we demonstrate the 
sustainable exploitation of marine natural resources providing 
appropriate culture conditions for the group of marine fungi, thus 
enabling efficient production of marine natural products in the 
laboratory and also in large scale cultures, avoiding harm to the 
natural environment. In the focus are new anti-cancer compounds.  
Two approaches are used to gain effective producer strains (fig. 1): 
a) Candidate strains originating from our unique strain collection of 
marine fungi are characterised and optimised using molecular 
methods. The genomes of these strains are sequenced during the 
project (fig. 3). 
b) New fungi are isolated from unique habitats, i.e. tropical coral 
reefs, endemic macroalgae and sponges from the Mediterranean. 
Culture conditions for these new isolates are optimised for the 
production of new anti-cancer metabolites. 
Fig. 1 MARINE FUNGI is aimed to develop a 
process concept providing the technological 
basis for a sustainable use of marine microbial 
products in oncology. 
Characterisation of candidate structures to the 
stage of in vivo proof of concept 
The development of clinically relevant lead structures 
requires affords beyond screening: An interdisciplinary 
approach is necessary to characterise hit candidates to the 
stage of in vivo proof of concept ready to enter further drug 
development in order to valorise the results of the project. 
This includes the development of robust, sustainable 
processes for the production of these compounds. 
Therefore, the Kiel Centre for Marine Natural Products 
(KiWiZ) initiated and coordinates an EU FP7 research 
project, MARINE FUNGI, focussing on the development of 
anti-cancer drugs from marine fungi (fig. 1). MARINE 
FUNGI covers two approaches to gain effective producer 
strains, which will be led to the stage of in vivo proof of 
concept building the basis for clinical trials (fig. 1, 2). 
 
Bildunterschrift in hellblau 
Fig. 2 MARINE FUNGI formed of a new strongly interacting research network comprising the scientific and technological 
actors, including 3 SMEs and 2 ICPC partners. Corals, algae and sponges are the sources for new fungal metabolites. 
More than 500 isolates are screened for their secondary metabolites until the end of 2012. 
Current status of MARINE FUNGI 
• Three fungal genomes are sequenced. The search for 
biosynthetic and regulatory genes is ongoing. 
• More than 500 new fungal isolates were gained, taxonomic 
affiliation is done by molecular and microscopic methods. 
• New strains are cryoconserved and established as the projects 
strain collection. 
• Nearly 2500 extracts were screened in the preliminary panel. 
• 50 compounds were screened in the full panel leading to a 
selection of 6 compounds ready for liability testing. 
• A process concept for these compounds is build comprising 
fermentation in stirred tank reactors and subsequent purification. 
• S. brevicaulis is oprimised by mutagenesis experiments, a library 
of UV mutants was established. 
• 8 PhD students are involved in MARINE FUNGI. 
• A website was set up, a weekly blog informs about news.  
WP1/2: Project Management and Ccoordination 
 
WP5 Chemical identification and 
biochemical characterisation of active 
metabolites and substance purification 
WP3 Genome analysis, identification 
of biosynthetic 
genes and regulators 
WP7 In vitro bioassays for cancer 
targets, rational lead structure 
selection and in vivo efficacy 
determination in xenograft models  
 
WP8 Robust and sustainable process 
development 
WP9: Intellectual Property protection & dissemination activities 
WP6 Strain improvement 
Selected fungal strains Selected macrobes from unique 
marine habitats 
Culture based approach Molecular based approach 
WP4 Isolation and identification of 
new fungal strains 
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Fig. 3 Three fungal strains were chosen for genome sequencing. 
The genomes will help to identify biosynthesis genes and give 
insights into regulatory features. 
Fig. 4 All extracts and pure compounds 
originating from the initial screening and 
subsequent purification are screened against 
various panels of cancer cell lines.  
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